Want to see GRI full AI Analyst Report?
Top Page
GRI Bio
(NASDAQ:GRI)
Select Model
Select Model
Rating:48Neutral
Price Target:
$1.50
▲(3.45% Upside)
Action:Reiterated
Date:08/19/26
The score is primarily held down by weak financial performance (no revenue, ongoing losses, and increasing cash burn) and limited valuation support (negative P/E, no dividend). Technicals are neutral with only modest near-term improvement. A meaningful positive offset is the Orphan Drug Designation, which strengthens the development outlook but does not remove near-term funding risk.
Positive Factors
Orphan Drug Designation
Orphan designation gives lasting regulatory advantages—potential seven years U.S. exclusivity, tax credits, fee waivers and closer FDA engagement. This materially improves the commercial and development economics of GRI-0621 and strengthens long-term partnership and funding prospects.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow at ~-$12M TTM indicates a structural funding need to continue development. This burn profile implies recurring capital raises or partnerships, increasing dilution risk and creating execution pressure on trial timelines and strategic options.
Read all positive and negative factors
Positive Factors
Negative Factors
Orphan Drug Designation
Orphan designation gives lasting regulatory advantages—potential seven years U.S. exclusivity, tax credits, fee waivers and closer FDA engagement. This materially improves the commercial and development economics of GRI-0621 and strengthens long-term partnership and funding prospects.
Read all positive factors
GRI Bio (GRI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.78M
Dividend YieldN/A
Average Volume (3M)82.65K
Price to Earnings (P/E)―
Beta (1Y)2.23
Revenue GrowthN/A
EPS Growth93.96%
CountryUS
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,186,115
10 Day Avg. Volume33,303
30 Day Avg. Volume82,652
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.11
Price to Sales (P/S)0.00
P/FCF Ratio-0.07
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$32.00Price Target Upside2106.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GRI Bio Business Overview & Revenue Model
Company Description
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product ca...
How the Company Makes Money
null...
GRI Bio Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.00K | -4.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -12.57M | -11.97M | -8.23M | -10.95M | -2.56M | -1.06M |
| Net Income | -12.55M | -11.96M | -8.21M | -13.04M | -3.22M | -1.56M |
Balance Sheet | ||||||
| Total Assets | 11.38M | 8.67M | 5.74M | 2.96M | 383.00K | 218.00K |
| Cash, Cash Equivalents and Short-Term Investments | 10.95M | 8.23M | 5.03M | 1.81M | 9.00K | 90.00K |
| Total Debt | 44.00K | 71.00K | 119.00K | 14.00K | 673.00K | 3.61M |
| Total Liabilities | 1.10M | 2.66M | 1.71M | 2.70M | 2.01M | 4.94M |
| Stockholders Equity | 10.28M | 6.01M | 4.03M | 259.00K | -1.63M | -4.72M |
Cash Flow | ||||||
| Free Cash Flow | -13.58M | -10.19M | -8.61M | -9.00M | -1.09M | -8.31M |
| Operating Cash Flow | -13.58M | -10.19M | -8.61M | -8.99M | -1.08M | -8.31M |
| Investing Cash Flow | -3.00K | -3.00K | 0.00 | -8.00K | -3.00K | -3.84M |
| Financing Cash Flow | 21.25M | 13.39M | 11.83M | 10.80M | 1.01M | 15.75M |
GRI Bio Technical Analysis
Negative
1.45
Price Trends
1.77
Negative
2.02
Negative
10.33
Negative
Market Momentum
0.02
Negative
51.84
Neutral
27.49
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRI, the sentiment is Negative. The current price of 1.45 is below the 20-day moving average (MA) of 1.58, below the 50-day MA of 1.77, and below the 200-day MA of 10.33, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 51.84 is Neutral, neither overbought nor oversold. The STOCH value of 27.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GRI.
GRI Bio Risk Analysis
GRI Bio disclosed 55 risk factors in its most recent earnings report. GRI Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GRI Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $3.78M | -0.04 | -199.52% | ― | ― | 93.96% | |
| ― | $2.41M | -0.15 | -177.32% | ― | ― | 86.26% | |
60 Neutral | $4.84M | >-0.01 | -72.72% | ― | -34.06% | 79.61% | |
33 Underperform | $2.99M | -0.09 | -105.46% | ― | -51.33% | 99.22% |
* Healthcare Sector Average
GRI
GRI Bio
1.71
-38.05
-95.70%
OGEN
Oragenics
0.55
-0.51
-48.49%
INM
InMed Pharmaceuticals
1.44
-0.81
-36.00%
KTTA
Pasithea Therapeutics Corp
0.50
-0.21
-30.00%
ONCO
Onconetix
0.75
-137.75
-99.46%
GRI Bio Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
GRI Bio Secures FDA Orphan Drug Status for IPF
Positive
Jun 18, 2026
On June 18, 2026, GRI Bio, Inc. announced that the U.S. Food and Drug Administration granted Orphan Drug Designation to its lead candidate GRI-0621 (tazarotene) for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disea...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.